Clinical Trial Update: Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating two doses of anifrolumab versus placebo in adults with active systemic lupus erythematosus, focusing on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Active Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2019-12-05